Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies
Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRAb) levels over that of methimazole monotherapy. Using a bioassay...
Description complète
Détails bibliographiques
| Publié dans: | Clinical immunology (Orlando, Fla.). - 1999. - 130(2009), 3 vom: 15. März, Seite 252-8
|
|---|
| Auteur principal: |
El Fassi, Daniel
(Auteur) |
|---|
| Autres auteurs: |
Banga, J Paul,
Gilbert, Jacqueline A,
Padoa, Carolyn,
Hegedüs, Laszlo,
Nielsen, Claus H |
|---|
| Format: | Article en ligne
|
|---|
| Langue: | English |
|---|
| Publié: |
2009
|
|---|
| Accès à la collection: | Clinical immunology (Orlando, Fla.)
|
|---|
| Sujets: | Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Autoantibodies
Immunoglobulins, Thyroid-Stimulating
Immunologic Factors
Rituximab
4F4X42SYQ6
plus...
Cyclic AMP
E0399OZS9N |
|---|